Cell signaling

Aptinyx to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 11, 2021

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.

Insights on the Erythropoietin (EPO) Global Market to 2030 - Identify Growth Segments for Investment

Retrieved on: 
Thursday, February 11, 2021

This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.
  • The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%.
  • It compares the erythropoietin (epo) market with other segments of the erythropoietin (epo) market by size and growth, historic and forecast.
  • The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.

PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery

Retrieved on: 
Tuesday, January 26, 2021

PerkinElmer , a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery .

Key Points: 
  • PerkinElmer , a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery .
  • These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.
  • For more information on the new kits and PerkinElmers extensive line up of GPCR offerings please visit: https://www.perkinelmer.com/category/gpcr-research-reagents and https://horizondiscovery.com/en/screening/screening-libraries .
  • We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

Trade, Track, And Learn Crypto With Hedgehog

Retrieved on: 
Tuesday, January 26, 2021

At Hedgehog, we care about teaching beginners so they can avoid all the pitfalls we fell into when we were getting started," said Taylor Culbertson, co-founder and CEO of Hedgehog.

Key Points: 
  • At Hedgehog, we care about teaching beginners so they can avoid all the pitfalls we fell into when we were getting started," said Taylor Culbertson, co-founder and CEO of Hedgehog.
  • "All the data on blockchains are public, and Hedgehog puts it all in one place," remarked Colton Dillion, co-founder and CTO of Hedgehog.
  • Hedgehog is a one-stop shop for all your cryptocurrency needs, allowing people to trade on almost any exchange, track all their wallets, and learn about every cryptocurrency.
  • Unify all your crypto services on one platform with Hedgehog.

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

Retrieved on: 
Monday, January 11, 2021

The Review proposes the repurposing of traditional central nervous system (CNS) drugs that have a high affinity at the sigma-1 receptor, naming Ifenprodil as a potential treatment of SARS-CoV-2-infected patients.

Key Points: 
  • The Review proposes the repurposing of traditional central nervous system (CNS) drugs that have a high affinity at the sigma-1 receptor, naming Ifenprodil as a potential treatment of SARS-CoV-2-infected patients.
  • The Review can be found here at Sigma-1 Receptor Research and was authored by Kenji Hashimoto and supported in part by the Japan Society for the Promotion of Science and the Japan Agency for Medical Research and Development.
  • Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Worldwide Railway Signalling Systems Industry to 2028 - Key Trends and Market Dynamics

Retrieved on: 
Thursday, January 7, 2021

Increasing demand for advance controlling systems and rising high-speed railway projects will drive the demand for railway signaling systems.

Key Points: 
  • Increasing demand for advance controlling systems and rising high-speed railway projects will drive the demand for railway signaling systems.
  • This research study on the railway Signaling systems market provides an exhaustive analysis of market trends and dynamics in the global industry.
  • The study also includes key market driving and restraining factors in the global railway Signaling systems market.
  • Which key trends and market dynamics influencing the growth of the global railway signaling systems industry?

Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference

Retrieved on: 
Tuesday, January 5, 2021

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021.
  • The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6:00 AM ET on Monday, January 11, 2021.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Retrieved on: 
Wednesday, December 30, 2020

TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8.

Key Points: 
  • TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8.
  • TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two.
  • When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner.
  • Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group.

lino Biotech closes seed financing round and showcases a novel label-free biosensor platform for innovate modern drug screening

Retrieved on: 
Tuesday, November 17, 2020

linos biosensor platform offers industry customers and researchers a unique way to study molecular interactions in living cells and crude biosystems.

Key Points: 
  • linos biosensor platform offers industry customers and researchers a unique way to study molecular interactions in living cells and crude biosystems.
  • Importantly, its broad application spectrum can for the first time, measure drug binding to transmembrane proteins while simultaneously observe intracellular signaling.
  • With access to modern clean room facilities, the company currently offers its services to selected industry partners as contract research service.
  • Dr. Mirko Stange, CEO of lino Biotech experiments with pharma partners have highlighted the value of Focal Molography.